FDA okays third antibody drug for mild-to-moderate Covid-19 cases
Washington, May 27
US health officials have granted emergency authorisation to a third antibody drug to help reduce hospitalisations and deaths due to Covid-19.
The FDA said Wednesday it authorised the drug from GlaxoSmithKline and Vir Biotechnology for people with mild-to-moderate cases of Covid-19 who face extra risks of severe illness, including seniors and those with underlying health problems.
There has been low demand for two similar drugs already available, due mainly to the logistical hurdles of delivering them and confusion about their availability. US health officials have been trying to raise awareness of the treatments, connecting people who test positive for Covid-19 with information about nearby providers.
The drugs are delivered as a one-time intravenous infusion at a hospital or clinic and should be given within 10 days of the start of symptoms. — AP
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.